Clinical studies of CAR-T therapy for LCa have published outcomes from a phase 1 trial in which EGFR CAR-T cells generated by the piggyBac transposon system were well tolerated by all patients with advanced relapsed/refractory EGFR(+) NSCLC (n = 9), with no reports of grade 4 adverse events or severe CRS (NCT03182816, CTCAE v5.0) [205]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.